APA

Bowler S., Siriwardhana C., Mitchell B. I., D'Antoni M. L., Ogata-Arakaki D., Souza S., Yee R., Gangcuangco L. M. A., Chow D. C., Ndhlovu L. C. & Shikuma C. (20200528). Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy. : HIV research & clinical practice.

Chicago

Bowler S, Siriwardhana C, Mitchell B I, D'Antoni M L, Ogata-Arakaki D, Souza S, Yee R, Gangcuangco L M A, Chow D C, Ndhlovu L C and Shikuma C. 20200528. Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy. : HIV research & clinical practice.

Harvard

Bowler S., Siriwardhana C., Mitchell B. I., D'Antoni M. L., Ogata-Arakaki D., Souza S., Yee R., Gangcuangco L. M. A., Chow D. C., Ndhlovu L. C. and Shikuma C. (20200528). Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy. : HIV research & clinical practice.

MLA

Bowler S, Siriwardhana C, Mitchell B I, D'Antoni M L, Ogata-Arakaki D, Souza S, Yee R, Gangcuangco L M A, Chow D C, Ndhlovu L C and Shikuma C. Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy. : HIV research & clinical practice. 20200528.